Vanguard Group Inc Myovant Sciences Ltd. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$24.03 - $27.02 $226,098 - $254,231	9,409 Added 1.14%	831,250 $22.4 Million
Q3 2022 Nov 14, 2022	SELL	$11.6 - $20.44 $432,842 - $762,698	-37,314 Reduced 4.34%	821,841 $14.8 Million
Q2 2022 Aug 12, 2022	BUY	$7.78 - $14.69 $592,198 - $1.12 Million	76,118 Added 9.72%	859,155 $10.7 Million
Q1 2022 May 13, 2022	SELL	$11.38 - $16.4 $58,299 - $84,017	-5,123 Reduced 0.65%	783,037 $10.4 Million
Q4 2021 Feb 14, 2022	SELL	$14.31 - $23.87 $177,229 - $295,629	-12,385 Reduced 1.55%	788,160 $12.3 Million
Q3 2021 Nov 12, 2021	BUY	$18.94 - $26.99 $496,758 - $707,893	26,228 Added 3.39%	800,545 $18 Million
Q2 2021 Aug 13, 2021	BUY	$17.07 - $24.56 $13.2 Million - $19 Million	774,317 New	774,317 $17.6 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.